Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMooi, Jennifer K-
dc.contributor.authorChionh, Fiona-
dc.contributor.authorSavas, Peter-
dc.contributor.authorDa Gama Duarte, Jessica-
dc.contributor.authorChong, Geoffrey-
dc.contributor.authorBrown, Stephen-
dc.contributor.authorWong, Rachel-
dc.contributor.authorPrice, Timothy-
dc.contributor.authorWann, Alysson-
dc.contributor.authorSkrinos, Effie-
dc.contributor.authorMariadason, John M-
dc.contributor.authorTebbutt, Niall C-
dc.identifier.citationClinical Cancer Research 2021; online first: 29 Januaryen
dc.description.abstractTo assess the efficacy and safety of dual anti-angiogenesis agents, bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer (mCRC). Open label Phase II study enrolled patients with unresectable mCRC with no prior systemic treatment. All patients received bevacizumab 7.5mg/kg 3-weekly and trebananib 15 mg/kg weekly. The primary endpoint was disease control (stable disease, partial (PR) or complete responses (CR)) at 6 months (DC6m). Secondary endpoints included toxicity, response rate (ORR), progression-free survival (PFS) and overall survival (OS). Exploratory biomarkers in plasma angiogenesis-related proteins, tumour gene expression and plasma antibodies to tumour antigens were examined. 45 patients were enrolled from four Australian sites. DC6m was 63% (95% CI: 47-77). ORR was 17% (95% CI: 7-32), comprising 7 PRs. Median duration of response was 20 months (range 10-48 months). Median PFS was 8.4 months and median OS 31.4 months. G1-2 peripheral oedema and joint-related symptoms were common. Overall incidence of G3-4 adverse events (AEs) of any type was 33% (n=15). Expected AEs of bevacizumab treatment did not appear to be increased by the addition of trebananib. In a first-line mCRC population, the dual anti-angiogenic combination, bevacizumab plus trebananib, was efficacious with durable responses. The toxicity profile of the combination was manageable and did not exceed that expected with bevacizumab +/-chemotherapy. Exploratory biomarker results suggest that in addition to its anti-angiogenic activity, this combination may provide clinical benefit by enabling anti-tumour immunomodulatory effects, supporting ongoing trials of anti-angiogenic therapy combined with cancer immunotherapy.en
dc.titleDual anti-angiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical Cancer Researchen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationResearch, Peter MacCallum Cancer Centreen
dc.identifier.affiliationSchool of Cancer Medicine, Olivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationMedical Oncology, Ballarat Regional Integrated Cancer Centreen
dc.identifier.affiliationMedical Oncology & Eastern Health Clinical School, Eastern Healthen
dc.identifier.affiliationOncology, Queen Elizabeth Hospitalen
dc.identifier.affiliationSchool of Medicine, University of Melbourneen
dc.identifier.affiliationAustin Healthen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.identifier.affiliationMedical Oncologyen
dc.identifier.pubmedid33514526, Geoffrey
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristype Newton-John Cancer Research Institute- Newton-John Cancer Wellness and Research Centre- Newton-John Cancer Wellness and Research Centre- Newton-John Cancer Research Institute- Oncology- Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Sep 28, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.